FY2025 EPS Estimates for Tourmaline Bio Reduced by Analyst

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2025 EPS estimates for Tourmaline Bio in a research report issued to clients and investors on Monday, May 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($3.71) for the year, down from their prior estimate of ($3.22). The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. Leerink Partnrs also issued estimates for Tourmaline Bio's FY2026 earnings at ($4.28) EPS, FY2027 earnings at ($5.89) EPS, FY2028 earnings at ($6.73) EPS and FY2029 earnings at ($3.45) EPS.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last posted its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($0.91) by $0.02.

Other equities analysts have also issued research reports about the company. Lifesci Capital assumed coverage on Tourmaline Bio in a research report on Monday, February 24th. They issued an "outperform" rating and a $58.00 price target for the company. Chardan Capital reiterated a "buy" rating and set a $70.00 price objective on shares of Tourmaline Bio in a research note on Monday, May 5th. HC Wainwright restated a "buy" rating and issued a $50.00 price target on shares of Tourmaline Bio in a research note on Monday, May 5th. Finally, Wedbush upped their price objective on Tourmaline Bio from $42.00 to $43.00 and gave the stock an "outperform" rating in a report on Friday, March 14th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $49.33.

Tourmaline Bio Stock Down 3.8%

Shares of TRML stock traded down $0.60 during mid-day trading on Thursday, reaching $15.18. 93,791 shares of the company's stock traded hands, compared to its average volume of 270,046. Tourmaline Bio has a 12 month low of $11.56 and a 12 month high of $29.79. The company has a market cap of $389.90 million, a P/E ratio of -5.38 and a beta of 2.11. The company's 50-day moving average price is $15.54 and its 200-day moving average price is $18.57.

Institutional Investors Weigh In On Tourmaline Bio

Large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of Tourmaline Bio by 7.7% in the 1st quarter. Vanguard Group Inc. now owns 1,190,810 shares of the company's stock valued at $18,112,000 after buying an additional 84,685 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of Tourmaline Bio in the 4th quarter valued at approximately $12,168,000. Velan Capital Investment Management LP lifted its holdings in shares of Tourmaline Bio by 28.0% in the 4th quarter. Velan Capital Investment Management LP now owns 423,795 shares of the company's stock valued at $8,595,000 after buying an additional 92,605 shares during the period. Pictet Asset Management Holding SA raised its holdings in Tourmaline Bio by 69.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 419,883 shares of the company's stock worth $8,515,000 after purchasing an additional 172,743 shares during the last quarter. Finally, Acuta Capital Partners LLC grew its stake in Tourmaline Bio by 5.9% in the 4th quarter. Acuta Capital Partners LLC now owns 351,842 shares of the company's stock valued at $7,135,000 after acquiring an additional 19,747 shares during the last quarter. Hedge funds and other institutional investors own 91.89% of the company's stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.